Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly and Company LLY reported first-quarter 2025 adjusted earnings per share (“EPS”) of $3.34, which missed the Zacks Consensus Estimate of $3.52 per share. Earnings rose 29% year over year.

Lilly’s injectable tirzepatide is sold under the brand names Mounjaro for diabetes and Zepbound for weight loss. Novo’s application is based on results from a late-stage trial, which studied ...

Lilly's leading position in weight loss and diabetes treatments ... also posted higher-than-expected quarterly results. It said lower prices for Zepbound trimmed revenue in the quarter, but ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

It's a brand name for tirzepatide — also known as Zepbound — which is highly effective for weight loss by reducing appetite ... changes to maintain the results. “I felt like, well, if ...

The increase in weight loss with the higher dose was impressive, but still lower than has been achieved in clinical trials of Eli Lilly's rival obesity therapy Zepbound (tirzepatide), which helped ...

CVS’s decision is expected to expand access to Novo’s weight-loss therapy, whilst limiting coverage for Lilly’s Zepbound ... have shown strong clinical results, while Novo’s once-promising ...